Loading…
Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.
Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.
Moat: none
Headquarters: Taiwan
Size PELL Bio-Med Technology (6949.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $1.49B, the 204th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$1,490 on 6 Nov 2026.
Performance Over six months the shares gained 125.8%, against -19.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 18 in its peer set.
Growth Revenue grew 5.5% over the last twelve months (peer median +23.4%); the operating margin is -1,719.9% (peer median -26.7%).
Valuation It trades at 1,640.0× enterprise value to sales against a peer median of 10.3× (most expensive of 16).
Capital Return on invested capital runs 47.2 points below its cost of capital (8.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$28.9M | NT$31.4M | NT$19.6M | NT$18.0M | NT$17.2M |
| Revenue growth | — | +60% | +9% | +5% | — |
| Gross profit | -NT$66.4M | -NT$51.5M | -NT$59.2M | -NT$71.8M | -NT$42.3M |
| EBITDA | -NT$434M | -NT$420M | -NT$367M | -NT$366M | -NT$205M |
| Net income | -NT$436M | -NT$424M | -NT$389M | -NT$399M | -NT$230M |
| Free cash flow | -NT$627M | -NT$508M | -NT$524M | -NT$196M | -NT$162M |
| Capital expenditure | NT$262M | NT$247M | NT$285M | NT$16.5M | NT$8.49M |
| Total debt | NT$232M | NT$237M | NT$365M | NT$173M | NT$203M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6949.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +67.2% | -5.0% | highest of 21 |
| 6-month return | +125.8% | -19.4% | 2nd highest of 18 |
| Distance from 52-week high | 0.0% | -41.7% | highest of 21 |
| Revenue growth (TTM) | +5.5% | +23.4% | 5th lowest of 17 |
| Operating margin | -1,719.9% | -26.7% | 2nd lowest of 17 |
| EV / Sales | 1,640.0× | 10.3× | most expensive of 16 |
| ROIC minus cost of capital | -47.2 pp | -8.7 pp | 5th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |